Blog

MNCs move SC over drug price control

Posted by admin on Nov 23, 2011 in Pharma News | 0 comments

Till now, pharma companies, opposing price control, have been trying to make their voices heard in the corridors of power. With the courts recently stepping in to bring essential medicines under a price control regime, multinational-led industry body OPPI (Organization of Pharmaceutical Producers of India) has moved the Supreme Court seeking to be heard on the drug pricing issue. OPPI through an application seeking “impleadment” in the ongoing public interest litigation on the drug pricing issue in the Supreme Court, wants to be a formal...

read more

Abbott, Dabur, GSK eye Jagdale’s energy drinks biz

Posted by admin on Nov 23, 2011 in Pharma News | 0 comments

A line-up of MNC and Indian bidders are in the fray to acquire home grown electrolyte energy drinks business of Jagdale Healthcare, which is on the block. GlaxoSmithKline Plc, Abbott Laboratories, Zydus Cadila, Wipro and Dabur are among the potential suitors for Jagdale’s OTC business for an estimated valuation of Rs 500 crore, said sources directly briefed on the matter. Bangalore-based Jagdale has appointed boutique investment bank Mape Advisory Group to find suitors for the business under the brand ORS-L. The brand, a patented...

read more

Heart attack between 1 & 5 am deadliest

Posted by admin on Nov 23, 2011 in Pharma Views | 0 comments

Study Reveals Brain Releases Hormones During Sleep Which Put Strain On The Organ Scientific studies have revealed that heart attacks are worst when they take place between 1 am and 5 am. Researchers say the size of the heart attack and the subsequent left-ventricular function is significantly different based on the time of the attack. A study on humans, published online in the reputed journal “Circulation Research”, says “the greatest amount of injury to the heart occurs when individuals have a heart attack between 1 am and 5 am”....

read more

New Policy to Cost Pharma Cos Rs. 1,500 cr

Posted by admin on Nov 22, 2011 in Pharma News | 0 comments

Stockists, traders may collectivey lose over Rs. 2,500 crore, says study; Lobby group wants price control only on 348 drugs The proposed national drug pricing policy will cost drug makers close to Rs. 1,500 crore and stockists and traders collectively over Rs. 2,500 crore in revenue loss when it comes into effect, a study shows. GlaxoSmithKline Pharmaceuticals’ loss has been pegged at Rs. 137 crore and Ranbaxy Laboratories’ at Rs. 115 crore, according to the study by pharmaceutical market research company AWACS. Others such as Abbott...

read more

Govt admits huge drug price differential

Posted by admin on Nov 18, 2011 in Pharma News | 0 comments

The National List of Essential Medicines (NLEM), 2011 has 348 medicines which cover 489 formulations, including 16 fixed dose combinations. These drugs are considered to be adequate to meet the common contemporary health needs of the general population of the country, the health ministry said. “It would be the general obligation of the health administrators to ensure abundant availability of these drugs,” it said. The bench agreed to give three months time to the government and posted the PIL filed by All India Drug Action Network for...

read more

Prices of 348 essential drugs to be controlled

Posted by admin on Nov 18, 2011 in Pharma News | 0 comments

New Delhi: The Centre on Thursday responded to the Supreme Court’s concern over spiralling prices of essential medicines and promised to make all-out efforts to put under strict price control regime all the 348 drugs included in the National List of Essential Medicines (NLEM), 2011. A bench comprising Justices G S Singhvi and S J Mukhopadhaya had, in the last hearing, expressed concern over the shrinking list of medicines under the Drug Price Control Order (DPCO) and had sought the Centre’s response on bringing NLEM medicines under price...

read more

Turn A Screw To Change Your Glasses

Posted by admin on Nov 16, 2011 in Pharma Views | 0 comments

Adjustable eyeglasses are set to revolutionise the world of vision care. Here’s a head-turning, new look at eyeglasses. No more rushing off to the optician for a new pair when the lens power changes. Simply readjust to the new power needs of your eyes by turning screws on the side. Much like you use and share binoculars, and adjust the focus by turning a screw in the middle, the adjustable eyeglasses will revolutionise vision care since the first pair of glasses were made in Italy more than 800 years ago. In case your eyeglasses break or you...

read more

1 in 5 Indians have diabetes, high BP

Posted by admin on Nov 16, 2011 in Pharma News | 0 comments

One in every five Indian adults living in urban cities suffers not only from hypertension but also diabetes. In Maharashtra, more disturbingly, one in three persons is struck by the twin epidemic. These are some of the highlights of India’s largest clinic-based survey to assess the prevalence of diabetes and hypertension. The findings of the study, called Screening India’s Twin Epidemic (SITE), were announced on Monday in Mumbai.

read more

Phosphagenics Licenses Diclofenac Gel for Indian Market

Posted by admin on Nov 16, 2011 in Pharma News | 0 comments

Phosphagenics Licenses Diclofenac Gel for Indian Market 2 November 2011, Melbourne, Australia: Melbourne drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), has licensed TPM/diclofenac, its topical non-steroidal pain formulation, to Themis Medicare Pvt Ltd of Mumbai for the Indian market. This represents Phosphagenics’ first commercial deal in India and its first licensing agreement of its diclofenac product. Under the terms of the agreement, Themis Medicare is committed to pay Phosphagenics an undisclosed...

read more

Using Consumer’s Intuitive Logic to influence OTC buying behaviour

Posted by admin on Nov 12, 2011 in Pharma Views | 0 comments

This article was written by Anil Khanna for Express Pharma as the Business Head of CubeX – Business Intelligence & Strategic Consulting Division of Sorento Healthcare Setting the context When it comes to communicating to the consumer, OTC medicines communication largely follows a uniform formula: Show the problem (in a realistic or exaggerated manner) or the consumer’s pain or agony due to the problem ?introduce the product ? show how it works (scientific method) ? then the relief ? ending with the brand benefit The end result is...

read more